Insect Cell, Per Se Patents (Class 435/348)
  • Publication number: 20130302859
    Abstract: The present disclosure provides engineered polypeptides having imine reductase activity, polynucleotides encoding the engineered imine reductases, host cells capable of expressing the engineered imine reductases, and methods of using these engineered polypeptides with a range of ketone and amine substrate compounds to prepare secondary and tertiary amine product compounds.
    Type: Application
    Filed: May 9, 2013
    Publication date: November 14, 2013
    Applicant: CODEXIS,INC.
    Inventors: CHEN Haibin, Steven J. Collier, Jovana NAZOR, Joly SUKUMARAN, Derek SMITH, Jeffrey C. MOORE, Gregory HUGHES, Jacob JANEY, Gjalt HUISMAN, Scott NOVICK, Nicholas AGARD, Oscar ALVIZO, Gregory COPE, Wan Lin YEO, Stephanie NG
  • Publication number: 20130305397
    Abstract: This invention relates to a cell comprising a reporter gene under control of an ARIA gene promoter, the cell being used for searching for an agent for prevention or treatment of diseases attributed to reduced insulin sensitivity, for searching for an obesity-controlling substance, or for searching for an obesity-inducing substance.
    Type: Application
    Filed: January 20, 2012
    Publication date: November 14, 2013
    Applicant: KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION
    Inventors: Koji Ikeda, Hiroaki Matsubara, Yoshiki Akakabe
  • Publication number: 20130295125
    Abstract: Methods and compositions for detecting MusPV, also known as MmuPv1, infection of a rodent subject are described according to aspects of the present invention. In specific aspects, the present invention relates to assays for detecting MusPV infection of a rodent subject; vaccine compositions for inducing an immunological response against MusPV in a rodent subject; methods of inducing an immunological response to MusPV in a rodent subject; isolated MusPV protein; isolated antibodies which specifically binds to an MusPV protein, a fragment or variant thereof; isolated recombinantly expressed MusPV proteins; expression constructs comprising a nucleic acid encoding an MusPV protein; host cells comprising the expression construct; and hybridoma cell lines expressing an anti-MusPV monoclonal antibody specific for MusPV.
    Type: Application
    Filed: March 14, 2013
    Publication date: November 7, 2013
    Applicants: UNIVERSITY OF LOUISVILLE RESEARCH FOUNDATION, THE JACKSON LABORATORY
    Inventors: John P. Sundberg, Joongho Joh, A. Bennett Jenson, Shin-Je Ghim
  • Publication number: 20130298264
    Abstract: The present invention relates generally to synthetic genes for modifying endogenous gene expression in a cell, tissue or organ of a transgenic organism, in particular a transgenic animal or plant. More particularly, the present invention provides novel synthetic genes and genetic constructs which are capable of repressing delaying or otherwise reducing the expression of an endogenous gene or a target gene in an organism when introduced thereto.
    Type: Application
    Filed: April 19, 2013
    Publication date: November 7, 2013
    Applicant: Commonwealth Scientific and Industrial Research Organisation
    Inventors: Michael Wayne Graham, Robert Norman Rice
  • Publication number: 20130296532
    Abstract: The present invention relates nucleic acid constructs for the production of recombinant parvoviral (e.g. adeno-associated viral) vectors in insect cells, to insect cells comprising such constructs and to methods wherein the cells are used to produce recombinant parvoviral virions. The insect cells preferably comprise a first nucleotide sequence encoding the parvoviral rep proteins whereby the initiation codon for translation of the parvoviral Rep78 protein is a suboptimal initiation codon that effects partial exon skipping upon expression in insect cells. The insect cell further comprises a second nucleotide sequence comprising at least one parvoviral (AAV) inverted terminal repeat (ITR) nucleotide sequence and a third nucleotide sequence comprising a sequences coding for the parvoviral capsid proteins.
    Type: Application
    Filed: July 18, 2013
    Publication date: November 7, 2013
    Inventors: Wilhelmus Theodorus Johannes Maria Christiaan HERMENS, Saskia Jacoba Petronella HAAST, Dennis Johan BIESMANS, Andrew Christian BAKKER
  • Publication number: 20130295666
    Abstract: The present invention pertains to crystals of glucokinase regulatory protein (GKRP) and of GKRP variants, to the molecular biology of certain GKRP variants, to processes for the crystallization of GKRP and GKRP variants, to such crystals and corresponding structural information obtained by X-ray crystallography. Such crystals and crystallographic data can be used for the identification of compounds that bind to GKRP, especially of compounds that inhibit GKRP or interfere with the interaction of GKRP with its natural interacting partner Glucokinase (GK).
    Type: Application
    Filed: December 17, 2012
    Publication date: November 7, 2013
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Gisela SCHNAPP, Adina Berg, Stefan Kauschke, Martin Lenter, Alexander Pautsch, Wolfgang Rist
  • Publication number: 20130296247
    Abstract: The present invention relates to a peptide and analogs thereof that selectively inhibit the Nav1.7 sodium channel. The present invention also relates to pharmaceutical compositions useful for treating or preventing a disorder responsive to the blockade of sodium ion channels, especially Nav1.7 sodium ion channels. The present invention further provides methods of treating a disorder responsive to the blockade of sodium channels, and particularly Nav1.7 sodium channels, in a mammal suffering from excess activity of said channels, compositions and methods for providing analgesia by administering a peptide of the invention.
    Type: Application
    Filed: July 7, 2011
    Publication date: November 7, 2013
    Applicant: PURDUE PHARMA L.P.
    Inventors: Jae Hyun Park, Donald J. Kyle
  • Publication number: 20130295610
    Abstract: Disclosed herein are compositions and methods for eliciting immune responses against antigens. In particular embodiments, the compounds and methods elicit immune responses against antigens that are otherwise recognized by the host as “self” antigens. The immune response is enhanced by presenting the host immune system with a chimeric antigen comprising an immune response domain and a target binding domain, wherein the target binding domain comprises a xenotypic antibody fragment. By virtue of the target binding domain, antigen presenting cells take up, process, and present the chimeric antigen, eliciting both a humoral and cellular immune response.
    Type: Application
    Filed: May 22, 2013
    Publication date: November 7, 2013
    Inventors: Rajan George, Lorne Tyrrell, Antoine Noujaim, Dakun Wang, Allan Ma
  • Publication number: 20130288301
    Abstract: The present invention relates to isolated polypeptides having endoglucanase activity, catalytic domains, cellulose binding domains and polynucleotides encoding the polypeptides, catalytic domains or cellulose binding domains. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides, catalytic domains or cellulose binding domains.
    Type: Application
    Filed: January 26, 2012
    Publication date: October 31, 2013
    Inventors: Nikolaj Spodsberg, Tarana Shagasi
  • Publication number: 20130288306
    Abstract: The invention relates to a fusion protein and a method for the generation of the fusion protein of the invention. Further, the invention relates to the use of the fusion protein of the invention for the generation of induced pluripotent cells. Moreover, the invention relates to a composition comprising at least one fusion protein of the invention.
    Type: Application
    Filed: July 8, 2013
    Publication date: October 31, 2013
    Inventors: Frank Edenhofer, Manal Bosnali, Michael Peitz, Marc-Christian Thier
  • Publication number: 20130291230
    Abstract: The present invention relates to isolated polypeptides having endoglucanase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: June 7, 2013
    Publication date: October 31, 2013
    Inventors: Alfredo Lopez de Leon, Michael Rey
  • Publication number: 20130288970
    Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas O2 delivery. The engineered H-NOX proteins comprise mutations that impart altered O2 or NO ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood O2 gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of O2 is beneficial.
    Type: Application
    Filed: February 20, 2013
    Publication date: October 31, 2013
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventor: The Regents Of The University Of California
  • Publication number: 20130288320
    Abstract: A method of increasing the production a difunctional alkane in a microorganism that produces a difunctional alkane from alpha-keto acid by increasing the production of homocitrate in the cell relative to a wild-type or parent cell. The production of homocitrate may be obtained by engineering pathways that increase the production of alpha-ketoacid, such as alpha-ketoglutarate.
    Type: Application
    Filed: April 23, 2013
    Publication date: October 31, 2013
    Applicant: BioAmber Inc.
    Inventor: Man Kit Lau
  • Publication number: 20130288299
    Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: January 26, 2012
    Publication date: October 31, 2013
    Applicant: Novozymes Inc.
    Inventor: Nikolaj Spodsberg
  • Publication number: 20130289252
    Abstract: H-NOX proteins are mutated to exhibit improved or optimal kinetic and thermodynamic properties for blood gas NO delivery. The engineered H-NOX proteins comprise mutations that impart altered NO or O2 ligand-binding relative to the corresponding wild-type H-NOX domain, and are operative as physiologically compatible mammalian blood NO gas carriers. The invention also provides pharmaceutical compositions, kits, and methods that use wild-type or mutant H-NOX proteins for the treatment of any condition for which delivery of NO is beneficial.
    Type: Application
    Filed: February 20, 2013
    Publication date: October 31, 2013
    Inventors: Stephen P. L. CARY, Elizabeth M. BOON, Jonathan A. WINGER, Michael A. MARLETTA
  • Publication number: 20130291234
    Abstract: The present invention relates to a gene encoding Synechocystis putative DNA binding stress protein (SyDBSP protein) derived from cyanobacteria Synechocystis PCC6906; a method for enhancing the salt tolerance of a plant comprising transforming a plant cell with a recombinant vector comprising the SyDBSP gene and overexpressing the SyDBSP gene; a plant having enhanced salt tolerance produced by the aforementioned method, and seed of the plant.
    Type: Application
    Filed: October 13, 2011
    Publication date: October 31, 2013
    Applicant: KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY
    Inventors: Jang Ryol Liu, Suk Weon Kim, Jong Hyun Kim, Sung Ran Min, Won Joong Jeong, Myung Suk Ahn, Young Min Park, Myung Jin Oh, Ji Hyun Park
  • Publication number: 20130273044
    Abstract: The present invention relates to compositions and methods for characterizing, diagnosing, and treating cancer. In particular the invention provides the means and methods for the diagnosis, characterization, prognosis and treatment of cancer and specifically targeting cancer stem cells. The present invention provides a soluble FZD receptor comprising an extracellular domain of a human FZD receptor that inhibits growth of tumor cells. The present invention still further provides a soluble receptor comprising a Fri domain of a human FZD receptor that binds a ligand of a human FZD receptor and said soluble receptor is capable of inhibiting tumor growth. The present invention still further provides a method of treating cancer comprising administering a soluble FZD receptor comprising for example, either an extracellular domain of a human FZD receptor or a Fri domain of a human FZD receptor, in an amount effective to inhibit tumor growth.
    Type: Application
    Filed: November 2, 2012
    Publication date: October 17, 2013
    Inventors: Austin GURNEY, John Lewicki, Sanjeev Satyal, Timothy Hoey
  • Publication number: 20130273028
    Abstract: The invention relates to variants of plasminogen and plasmin comprising one or more point mutations in the catalytic domain which reduce or prevent autocatylic destruction of the protease activity plasmin. Compositions, uses and methods of using said variants of plasminogen and plasmin are also disclosed.
    Type: Application
    Filed: January 4, 2012
    Publication date: October 17, 2013
    Applicant: ThromboGenics NV
    Inventor: Richard Reinier Zwaal
  • Publication number: 20130274172
    Abstract: The present invention relates generally to tissue differentiation factor (TDF) analogs. More specifically, the invention relates to structure-based methods and compositions useful in designing, identifying, and producing molecules which act as functional modulators of TDF-like receptors. The invention further relates to methods of detecting, preventing, and treating TDF-associated disorders.
    Type: Application
    Filed: March 26, 2013
    Publication date: October 17, 2013
    Inventors: William D. Carlson, Peter C. Keck
  • Publication number: 20130273611
    Abstract: Compositions and methods are provided for treating lignocellulosic material with a xylanase enzyme having xylanase activity. The enzyme is stable and active at increased pHs and temperatures. The present invention therefore provides methods for hydrolyzing lignocellulosic material, especially cellulose and hemicellulose, which are major components of the cell wall of non-woody and woody plants. The methods for hydrolyzing cellulose and hemicellulose can be used on any plant, wood or wood product, wood waste, paper pulp, paper product or paper waste or byproduct.
    Type: Application
    Filed: September 8, 2011
    Publication date: October 17, 2013
    Applicant: SYNGENTA BIOTECHNOLOGY INC.
    Inventors: John Steffens, Paul Oeller, Yoshimi Barron
  • Publication number: 20130273109
    Abstract: The invention provides a process for generating parvovirus VP1/VP2 virus like particles (VLPs). The invention further provides methods for purification of the parvovirus VLPs and immunogenic compositions that contain the VLPs. The invention also includes recombinant nucleic acid molecules that encode parvovirus VP1 and VP2, and host cells that contain the recombinant nucleic acids.
    Type: Application
    Filed: April 7, 2011
    Publication date: October 17, 2013
    Applicant: NOVARTIS AG
    Inventors: Ethan Settembre, Angelica Medina-Selby, Doris Coit, Philip R. Dormitzer
  • Publication number: 20130273553
    Abstract: In various aspects, the invention provides methods for cyclizing proteins, including methods for enhancing the stability of cyclized proteins under cytosolic conditions. The invention also provides various methods for using the cyclized proteins. For example, cyclized proteins of the invention may be used in screening assays analogous to the yeast two hybrid assay. Selected embodiments of the invention provide cyclized single chain variable fragment (ScFv) molecules, including molecules in the form of an immunoglobulin fold.
    Type: Application
    Filed: January 10, 2008
    Publication date: October 17, 2013
    Inventor: Ronald C. Geyer
  • Publication number: 20130267002
    Abstract: The present invention relates to polypeptides having glucoamylase activity and polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: June 12, 2013
    Publication date: October 10, 2013
    Inventors: Sara Landvik, Marc Dominique Morant, Keiichi Ayabe, Guillermo Coward-Kelly
  • Publication number: 20130260420
    Abstract: The present invention relates to isolated polypeptides having cellobiohydrolase activity and isolated polynucleotides encoding the polypeptides. The invention also relates to nucleic acid constructs, vectors, and host cells comprising the polynucleotides as well as methods of producing and using the polypeptides.
    Type: Application
    Filed: January 26, 2012
    Publication date: October 3, 2013
    Inventors: Marc D. Morant, Paul Harris
  • Patent number: 8546105
    Abstract: Methods for manipulating carbohydrate processing pathways in cells of interest are provided. Methods are directed at manipulating multiple pathways involved with the sialylation reaction by using recombinant DNA technology and substrate feeding approaches to enable the production of sialylated glycoproteins in cells of interest. These carbohydrate engineering efforts encompass the implementation of new carbohydrate bioassays, the examination of a selection of insect cell lines and the use of bioinformatics to identify gene sequences for critical processing enzymes. The compositions comprise cells of interest producing sialylated glycoproteins. The methods and compositions are useful for heterologous expression of glycoproteins.
    Type: Grant
    Filed: August 9, 2010
    Date of Patent: October 1, 2013
    Assignees: The University of Wyoming, The John Hopkins University, Human Genome Sciences, Inc.
    Inventors: Donald Jarvis, Michael J. Betenbaugh, Shawn Lawrence, Yuan C. Lee, Timothy A. Coleman
  • Publication number: 20130252282
    Abstract: Engineered fusion proteins comprising photochromic protein domains are disclosed. In particular, the inventors have constructed fusion proteins containing photoswitchable photochromic fluorescent protein domains linked to selected proteins and shown that such fusion proteins can be used to control the activity or localization of selected proteins with light.
    Type: Application
    Filed: March 21, 2013
    Publication date: September 26, 2013
    Applicant: The Board of Trustees of the Leland Stanford Junior University
    Inventor: The Board of Trustees of the Leland Stanford Junior University
  • Publication number: 20130252307
    Abstract: The invention provides a method for increasing the stability and/or activity of a polypeptide at low pH and/or elevated temperatures. The invention further provides a method for increasing the melting temperature of a polypeptide. Also provided are paleoenzymologically reconstructed thioredoxin polypeptides having activity at higher temperatures and/or lower pH than extant thioredoxin polypepetides, as well as paleoenzymologically reconstructed thioredoxin polypeptides having higher melting temperatures than extant thioredoxin polypepetides.
    Type: Application
    Filed: July 15, 2011
    Publication date: September 26, 2013
    Applicant: GEORGIA TECH RESEARCH CORPORATION
    Inventors: Julio M. Fernandez, Raul Perez-Jimenez, Eric Gaucher, Pallav Kosuri
  • Publication number: 20130254930
    Abstract: The invention provides promoter sequences that regulate specific expression of operably linked sequences in developing xylem cells and/or in developing xylem tissue. The developing xylem-specific sequences are exemplified by the DX5, DX8, DX11, and DX15 promoters, portions thereof, and homologs thereof. The invention further provides expression vectors, cells, tissues and plants that contain the invention's sequences. The compositions of the invention and methods of using them are useful in, for example, improving the quantity (biomass) and/or the quality (wood density, lignin content, sugar content etc.) of expressed biomass feedstock products that may be used for bioenergy, biorefinary, and generating wood products such as pulp, paper, and solid wood.
    Type: Application
    Filed: September 13, 2011
    Publication date: September 26, 2013
    Applicant: BOARD OF TRUSTEES OF MICHIGAN STATE UNIVERSITY
    Inventors: Kyung-Hwan Han, Jae-Heung Ko
  • Publication number: 20130252284
    Abstract: This invention provides a novel cellulase derived from Thermosporothrix hazakensis. The cellulase derived from Thermosporothrix hazakensis has enzyme activity on at least ?-glucan, soluble cellulose, crystalline cellulose, phosphoric acid-swollen cellulose, and xylan.
    Type: Application
    Filed: May 31, 2012
    Publication date: September 26, 2013
    Applicant: Kennan Eisei Kogyo Co., Ltd.
    Inventors: Shuhei Yabe, Yoshifumi Aiba, Yasuteru Sakai, Akira Yokota
  • Publication number: 20130243789
    Abstract: Disclosed are useful constructs and methods for the expression of proteins using primary translation products that are processed within a recombinant host cell. Constructs comprising a single open reading frame (sORF) are described for protein expression including expression of multiple polypeptides. A primary translation product (a pro-protein or a polyprotein) contains polypeptides such as inteins or hedgehog family auto-processing domains, or variants thereof, inserted in frame between multiple protein subunits of interest. Also disclosed are independent aspects of conducting efficient expression, secretion, and/or multimeric assembly of proteins such as immunoglobulins.
    Type: Application
    Filed: January 11, 2013
    Publication date: September 19, 2013
    Applicant: Abbott Laboratories
    Inventors: Gerald R. Carson, Jochen G. Salfeld, Dean A. Regier, Jijie Gu, Wendy Gion, Yune Z. Kunes
  • Publication number: 20130243799
    Abstract: The present invention provides a novel cancer-associated antigen that can be used in the treatment and diagnosis of cancer. Further, the invention provides amino acid and nucleic acid sequence of the novel antigen, binding proteins, and immunoconjugates. The invention also relates to diagnostic and therapeutic methods and kits.
    Type: Application
    Filed: January 25, 2013
    Publication date: September 19, 2013
    Applicant: VIVENTIA BIOTECHNOLOGIES INC.
    Inventors: Francina C. CHAHAL, Glen MACDONALD, Jeannick CIZEAU
  • Publication number: 20130243690
    Abstract: The invention generally features compositions and methods based on the structure-based design of alpha 1-3 N-Acetylgalactosaminyltransferase (alpha 3 GalNAc-T) enzymes from alpha 1-3galactosyltransferase (a3Gal-T) that can transfer 2?-modified galactose from the corresponding UDP-derivatives due to substitutions that broaden the alpha 3Gal-T donor specificity and make the enzyme a3 GalNAc-T.
    Type: Application
    Filed: April 11, 2013
    Publication date: September 19, 2013
    Applicant: Government of the United Sates of America, as represented by the Secretary Department of Health
    Inventors: Pradman K. Qasba, Boopathy Ramakrishnan, Elizabeth Boeggeman, Marta Pasek
  • Publication number: 20130244292
    Abstract: The present invention relates to a family 5 glycoside hydrolase variant having endoglucanase activity, polynucleotides encoding the family 5 glycoside hydrolase variant, vectors, host cells comprising the polynucleotides, and methods for using the family 5 glycoside hydrolase variant.
    Type: Application
    Filed: March 15, 2013
    Publication date: September 19, 2013
    Applicant: BP Corporation North America Inc.
    Inventors: John Poland, Justin T. Stege
  • Publication number: 20130244277
    Abstract: The present invention provides a host cell suitable for enhanced production of a protein product of choice characterised in that the host cell is genetically modified to cause over-expression of two or more helper proteins selected from a DnaJ-like protein (such as JEM1), an Hsp70 family protein (such as LHS1) and SIL1, wherein at least one of the over-expressed two or more helper proteins is selected from JEM1, LHS1 and SIL1, and wherein the DnaJ-like protein is not SCJ1.
    Type: Application
    Filed: March 4, 2013
    Publication date: September 19, 2013
    Applicants: UNIVERSITY OF NOTTINGHAM, NOVOZYMES BIOPHARMA DK A/S
    Inventors: Thomas Payne, Darrell Sleep, Christopher John Arthur Finnis, Leslie Robert Evans
  • Publication number: 20130243796
    Abstract: The invention relates to the identification of genetic products that are expressed in association with a tumor and the nucleic acid coding therefor. The invention relates to the therapy and diagnosis of diseases in which the genetic products that are expressed in association with a tumor are expressed in an aberrant manner. The invention also relates to proteins, polypeptides, and peptides which are expressed in association with a tumor and the nucleic acids coding therefor.
    Type: Application
    Filed: March 12, 2013
    Publication date: September 19, 2013
    Inventors: Ugur Sahin, Özlem Türeci, Michael Koslowski
  • Publication number: 20130243755
    Abstract: A purified polypeptide, designated ULIP6, comprising the amino acid sequence SED ID No. 2 or an epitopic fragment of said polypeptide, comprising the sequence SEQ ID No. 4, is provided along with its nucleic acid sequences. In addition, antibodies to the polypeptide and methods of diagnosing paraneoplastic neurological syndromes and/or for the early diagnosis of the formation of cancerous tumors are also provided.
    Type: Application
    Filed: January 15, 2013
    Publication date: September 19, 2013
    Applicant: INSTITUT NATIONAL DE LA SANTA ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventor: Institut National De La Santa Et De La Recherche Medicale (INSERM)
  • Publication number: 20130237486
    Abstract: The present invention relates to a trimeric fusion protein comprising three polypeptide chains, wherein each polypeptide chain comprises a eukaryotic collagen or collagen-like domain and a prokaryotic or viral trimerisation domain (PVTD). Also provided is a fusion polypeptide comprising a eukaryotic collagen or collagen-like domain and a PVTD. A suitable PVTD of a fusion polypeptide or protein of the invention is preferably derived from a collagen-like protein sequence found in the genome of the E. coli strain O157:H7 and other E. coli strains, and in bacteriophages or prophages infecting these strains or embedded in their genomes. A PVTD mediates trimerisation of collagen or collagen like polypeptides.
    Type: Application
    Filed: November 14, 2011
    Publication date: September 12, 2013
    Applicant: The University of Manchester
    Inventor: Jordi Bella
  • Publication number: 20130239236
    Abstract: The present invention describes mRNA usage improving and/or translation-enhancing nucleic acid sequences, nucleic acid constructs comprising such sequences, and host cells comprising such nucleic acid constructs. The invention further pertains to a method for expressing a protein of interest in a cell or organism using such nucleic acid sequences, as well as their uses for increasing integration of such nucleic acid construct into a genome, for enhancing mRNA usage and/or translation of a recombinantly expressed polypeptide, and for increasing the number of transformants upon transformation of a cell with such nucleic acid construct.
    Type: Application
    Filed: September 30, 2011
    Publication date: September 12, 2013
    Applicant: R1 B3 Holdings B.V.
    Inventors: Raymond Michael Dimphena Verhaert, Pieter Victor Schut, Sharief Barends, Maurice Wilhelmus van der Heijden
  • Publication number: 20130237474
    Abstract: Modified biosynthetic polypeptide fusion inhibitors, methods for manufacturing, and uses thereof are provided.
    Type: Application
    Filed: November 13, 2012
    Publication date: September 12, 2013
    Applicant: AMBRX, INC.
    Inventors: Roberto Mariani, Bruce E. Kimmel
  • Publication number: 20130230852
    Abstract: The present disclosure provides methods and compositions for diagnosis and for providing a prognosis of a cancer patient by assessing CK2 alpha 1 pseudogene (CSNK2A1P) status. The present disclosure also provides polypeptide, polynucleotide, host cell, and transgenic animal compositions associated with CSNK2A1P.
    Type: Application
    Filed: July 1, 2011
    Publication date: September 5, 2013
    Applicant: The Regents of the University of California
    Inventors: Liang You, Zhidong Xu, Biao He, David Jablons
  • Publication number: 20130230889
    Abstract: The present invention notably relates to ulvan lyases, to nucleic acid sequences coding for these ulvan lyases, to vectors comprising these coding sequences, to a method of manufacturing these ulvan lyases, as well as to a method of degrading ulvans using these ulvan lyases and applicable applications to the degradation products of the ulvans. The ulvan lyases of the present invention, or ulvanolytic protein, are notably defined as proteins of 30 or 46 kD comprising the following four sequences in their peptide sequence: PNDPNLK, LLEVGNTGTFGSTGS, DLANPDNV and WNLPE.
    Type: Application
    Filed: June 16, 2011
    Publication date: September 5, 2013
    Applicant: UNIVERSITE PIERRE ET MARIE CURIE
    Inventors: William Helbert, Pi Nyvall-Collen, Yannick Lerat, Jean-François Sassi
  • Publication number: 20130232642
    Abstract: Isolated polynucleotides and polypeptides and recombinant DNA constructs useful for conferring drought tolerance, compositions (such as plants or seeds) comprising these recombinant DNA constructs, and methods utilizing these recombinant DNA constructs. The recombinant DNA construct comprises a polynucleotide operably linked to a promoter that is functional in a plant, wherein said polynucleotide encodes a PRE2 polypeptide.
    Type: Application
    Filed: June 27, 2012
    Publication date: September 5, 2013
    Inventors: Stephen M. Allen, Rajeev Gupta, Shuping Jiao, Robert B. Meeley, Dilbag S. Multani, Robert Williams
  • Publication number: 20130230855
    Abstract: Nucleic acids encoding various monocyte-derived proteins and related compositions, including purified proteins and specific antibodies are described. Methods of using such composition are also provided.
    Type: Application
    Filed: April 19, 2013
    Publication date: September 5, 2013
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: ELIZABETH BATES, NATHALIE FOURNIER, LIONEL CHALUS, PIERRE GARRONE
  • Publication number: 20130224855
    Abstract: The invention pertains to the use of amino acid derivatives selected from N-acetyl amino acids, ?-glutamyl amino acids, pyroglutamyl amino acids, glutamate-containing or proline-containing dipeptides, oxo-aminoacids, homo-aminoacids, and glycyl-glycine, as a growth- and production promoting ingredient, in culture media for culturing eukaryotic cells. The invention further pertains to culture media containing these amino acid derivatives at levels of at least 0.001 mg/l.
    Type: Application
    Filed: August 31, 2011
    Publication date: August 29, 2013
    Inventors: Abhishek Gupta, Mireille Maria Gadellaa, Dominick Yves Willy Maes
  • Publication number: 20130224809
    Abstract: Provided herein are diterpene synthases (diTPS) and methods for producing diterpenoids. Also provided herein are nucleic acid sequences encoding diTPS, diTPS amino acid sequences, diTPS proteins, vectors, cells, transgenic organisms, uses, compositions, methods, processes, and kits thereof.
    Type: Application
    Filed: November 21, 2012
    Publication date: August 29, 2013
    Inventors: Joerg Bohlmann, Philipp Zerbe
  • Publication number: 20130224828
    Abstract: Protein nanoparticles encapsulate cargo proteins within an enclosure containing a protected chemical milieu. Encapsulation within such protected chemical milieu enhances the employability and performance of cargo proteins, particularly cargo enzymes, particularly within otherwise hostile chemical environments. Protein nanoparticles are assembled using shell proteins, such as viral coat proteins like Q?, in the presence of a bifunctional polynucleotide and the selected cargo protein. The bifunctional polynucleotide includes two aptameric activities that assist the disposition and retention of cargo proteins within the protein nanoparticle.
    Type: Application
    Filed: November 1, 2011
    Publication date: August 29, 2013
    Applicant: QAPSULE TECHNOLOGIES, INC.
    Inventors: M.G. Finn, Steven Brown, Jason Fiedler
  • Publication number: 20130225451
    Abstract: The present invention provides materials and methods useful for error correction of nucleic acid molecules. In one embodiment of the invention, a first plurality of double-stranded nucleic acid molecules having a nucleotide mismatch are fragmented by exposure to a molecule having unidirectional mismatch endonuclease activity. The nucleic acid molecules are cut at the mismatch site or near the mismatch site, leaving a double-stranded nucleic acid molecule having a mismatch at the end or near end of the molecule. The nucleic acid molecule is then exposed to a molecule having unidirectional exonuclease activity to remove the mismatched nucleotide. The missing nucleotides can then be filled in by the action of, e.g., a molecule having DNA polymerase activity. The result is double-stranded nucleic acid molecules with a decreased frequency of nucleotide mismatches.
    Type: Application
    Filed: February 1, 2013
    Publication date: August 29, 2013
    Applicant: SYNTHETIC GENOMICS, INC.
    Inventor: SYNTHETIC GENOMICS, INC.
  • Publication number: 20130217068
    Abstract: The present invention relates to nucleic acid and amino acid sequences from Akkermansia muciniphila and from Bacteroides fragilis, coding for/representing novel alpha-1,3-fucosyltransferases. The invention also provides uses and methods for using the alpha-1,3-fucosyltransferases to generate fucosylated products, such as oligosaccharides, (glyco)proteins, or (glyco)lipids, in particular of 3-fucosyllactose.
    Type: Application
    Filed: April 10, 2013
    Publication date: August 22, 2013
    Applicant: JENNEWEIN BIOTECHNOLOGIE GMBH
    Inventor: JENNEWEIN BIOTECHNOLOGIE GMBH
  • Publication number: 20130217625
    Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.
    Type: Application
    Filed: April 11, 2013
    Publication date: August 22, 2013
    Applicant: Amgen Inc.
    Inventor: Amgen Inc.
  • Publication number: 20130217612
    Abstract: The present invention includes the complete genome sequence for the methanogen, Methanobrevibacter ruminantium, including polynucleotides which encode M. ruminantium polypeptides or peptides, as well as polynucleotides from non-coding regions. Also included are the encoded M. ruminantium polypeptides and peptides, and antibodies directed to these peptides or polypeptides, in addition to expression vectors and host cells for producing these peptides, polypeptides, polynucleotides, and antibodies. The invention further includes methods and compositions for detecting, targeting, and inhibiting microbial cells, especially methanogen cells such as M. ruminantium cells, using one or more of the disclosed peptides, polypeptides, polynucleotides, antibodies, expression vectors, and host cells.
    Type: Application
    Filed: August 27, 2010
    Publication date: August 22, 2013
    Inventors: Eric Heinz Altermann, Graeme Trevor Attwood, Gregory Cook, Debjit Dey, Scott A. Ferguson, Petrus Hendricus Janssen, William John Kelly, Zhanhao Kong, Suzanne Lambie, Sinead Christine Leahy, Dong Li, Duncan McMillan, Sharla McTavish, Diana Pacheco, Robert Starr Ronimus, Carrie Sang, Carl Yeoman